VolitionRx publishes Nu.Q NETs platform update presentation on sepsis biomarker data
VNRX•Nu.Q NETs sepsis update
Volition published a presentation updating clinical and scientific evidence for its Nu.Q NETs assay, positioning Nu.Q H3.1 for sepsis management.
Presentation: https://volition.com/wp-content/uploads/2026/07/NETs-summary-slide-July-26-1.pdf
Clinical evidence and commercial outlook
The update cites consistent international findings that H3.1 nucleosomes distinguish sepsis from non-infectious inflammation, correlate with severity, and support prognosis.
The presentation states H3.1 adds information beyond standard organ failure scores such as APACHE II and SOFA.
The commercial update flags discussions with large diagnostics groups, and the total addressable market is estimated at about $3.8 billion annually.
